A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma
B-Cell Lymphoma
DRUG: IBI301|DRUG: Rituximab
AUC0-inf of IBI301 and rituximab, 91 days
Peak Plasma Concentration (Cmax), 91 days|Percentage and absolute value of CD19+, 91 days|Percentage and absolute value of CD20+ B-cell, 91 days|Positive rate of ADA, 91 days|Positive rate of NAb, 91 days|Safety profiles, Including AE type、incidence rate、severity and drug- related, up to 1 year|Area under the plasma concentration versus time curve (AUC), 91days|AUC（0-t） of IBI301 and rituximab, 91 days
Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma